Walmsley Looks Safe For Now, But GSK Faces M&A Pressure

Strategy Debate Will Rumble On

Moves by Elliott Advisors to split up GSK and unseat Emma Walmsley look unlikely to succeed, but have already created pressure for more deal-making.

GSK — Major investors have backed Emma Walmsley as CEO - but will want to see their patience rewarded

Major investors in GlaxoSmithKline plc have given their backing to its chief executive Emma Walmsley’s plans for the company, despite renewed calls for change from activist investor Elliott Advisors last week.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Walmsley Looks Safe For Now, But GSK Faces M&A Pressure

Strategy Debate Will Rumble On

Read the full article – start your free trial today!

More from Business

More from Scrip